LMR Georgette PMHNP Board Exam Review 2026/2027 –
Complete Exam-Style Questions with Detailed Rationales | 100%
Verified – Pass Guaranteed – A+ Graded
How to Use This Review
Work through all 50 questions under timed conditions (75–90 minutes). Review the
High-Yield Tables and Pharmacology Rapid Reference before attempting questions. Use
the Clinical Pearls to reinforce commonly tested concepts. Read every rationale in Part
5, even for questions answered correctly.
PART 1: HIGH-YIELD CONTENT SUMMARY TABLES
Table
Domain Key Concepts Must-Know Facts LMR Georgette Pearl
,1. Mood MDD (SIGECAPS), MDD = 5/9 symptoms Bipolar I mania = 7+
Disorders PDD, Bipolar I/II, × 2 weeks; PDD = 2+ days or
Cyclothymia symptoms × 2 years; hospitalization; Bipolar
Bipolar I requires full II never has full mania
manic episode
2. Anxiety GAD, Panic, Social GAD = 6+ months, 3+ PTSD intrusive
& Trauma Anxiety, PTSD, Acute symptoms; PTSD = >1 symptoms differ from
Stress month after trauma; GAD worry by
Acute Stress = 3 presence of
days–1 month re-experiencing
3. Schizophrenia, Schizophrenia = 6+ Schizoaffective
Psychotic Schizoaffective, months; requires mood
Disorders Schizophreniform, Schizophreniform = episode + psychosis,
Delusional 1–6 months; but psychosis must
Schizoaffective = persist independently
psychosis ≥2 weeks
without mood
symptoms
4. Monoamine NMDA hypofunction in Don't forget: psychosis
Neurobiolo hypothesis, glutamate, schizophrenia; BDNF can be NMDA receptor
gy HPA axis, reduction in antibody-mediated—m
neuroplasticity edical workup matters
, depression; cortisol
dysregulation in PTSD
5. SSRI, SNRI, NaSSA, SSRIs first-line for Fluoxetine &
Antidepres MAOI, TCA, atypical MDD, GAD, OCD; paroxetine are strong
sants MAOIs require CYP2D6 inhibitors;
tyramine restriction; mirtazapine is weight
TCAs lethal in gain friendly
overdose
6. First-gen (typical), FGAs = high EPS/TD Clozapine = ANC
Antipsycho Second-gen (atypical) risk; SGAs = metabolic monitoring;
tics syndrome risk; agranulocytosis risk
clozapine = highest in first 3
treatment-resistant + months
TRMS
7. Mood Lithium, valproate, Lithium: 0.6–1.2 Lamotrigine requires
Stabilizers lamotrigine, mEq/L; teratogen slow titration; risk of
carbamazepine (Ebstein anomaly); SJS/TEN highest at
check TSH, Cr, WBC initiation
, 8. Benzodiazepines, Benzos = GABA-A Benzo withdrawal can
Anxiolytics buspirone, Z-drugs, agonists; avoid in cause seizures; taper
& hydroxyzine elderly (BEERS); slowly, especially
Hypnotics buspirone = serotonin alprazolam
1A partial agonist, no
dependence
9. CBT, DBT, IPT, MI, CBT = cognitive DBT is first-line for
Psychother Exposure, Family distortions + BPD; CBT is first-line
apy behavioral activation; for MDD, GAD, panic,
DBT = 4 modules for PTSD
BPD; MI = OARS for
SUD
10. Capacity, Tarasoff, Capacity = Zuranolone = oral for
Legal/Ethic involuntary decision-specific; PPD; brexanolone = IV
s & Special commitment, Tarasoff = duty to for PPD; SSRIs = black
Population perinatal, geriatric, warn/protect box <25 years
s SUD identifiable victims;
minors = consent
varies by state
PART 2: PRACTICE QUESTIONS
Complete Exam-Style Questions with Detailed Rationales | 100%
Verified – Pass Guaranteed – A+ Graded
How to Use This Review
Work through all 50 questions under timed conditions (75–90 minutes). Review the
High-Yield Tables and Pharmacology Rapid Reference before attempting questions. Use
the Clinical Pearls to reinforce commonly tested concepts. Read every rationale in Part
5, even for questions answered correctly.
PART 1: HIGH-YIELD CONTENT SUMMARY TABLES
Table
Domain Key Concepts Must-Know Facts LMR Georgette Pearl
,1. Mood MDD (SIGECAPS), MDD = 5/9 symptoms Bipolar I mania = 7+
Disorders PDD, Bipolar I/II, × 2 weeks; PDD = 2+ days or
Cyclothymia symptoms × 2 years; hospitalization; Bipolar
Bipolar I requires full II never has full mania
manic episode
2. Anxiety GAD, Panic, Social GAD = 6+ months, 3+ PTSD intrusive
& Trauma Anxiety, PTSD, Acute symptoms; PTSD = >1 symptoms differ from
Stress month after trauma; GAD worry by
Acute Stress = 3 presence of
days–1 month re-experiencing
3. Schizophrenia, Schizophrenia = 6+ Schizoaffective
Psychotic Schizoaffective, months; requires mood
Disorders Schizophreniform, Schizophreniform = episode + psychosis,
Delusional 1–6 months; but psychosis must
Schizoaffective = persist independently
psychosis ≥2 weeks
without mood
symptoms
4. Monoamine NMDA hypofunction in Don't forget: psychosis
Neurobiolo hypothesis, glutamate, schizophrenia; BDNF can be NMDA receptor
gy HPA axis, reduction in antibody-mediated—m
neuroplasticity edical workup matters
, depression; cortisol
dysregulation in PTSD
5. SSRI, SNRI, NaSSA, SSRIs first-line for Fluoxetine &
Antidepres MAOI, TCA, atypical MDD, GAD, OCD; paroxetine are strong
sants MAOIs require CYP2D6 inhibitors;
tyramine restriction; mirtazapine is weight
TCAs lethal in gain friendly
overdose
6. First-gen (typical), FGAs = high EPS/TD Clozapine = ANC
Antipsycho Second-gen (atypical) risk; SGAs = metabolic monitoring;
tics syndrome risk; agranulocytosis risk
clozapine = highest in first 3
treatment-resistant + months
TRMS
7. Mood Lithium, valproate, Lithium: 0.6–1.2 Lamotrigine requires
Stabilizers lamotrigine, mEq/L; teratogen slow titration; risk of
carbamazepine (Ebstein anomaly); SJS/TEN highest at
check TSH, Cr, WBC initiation
, 8. Benzodiazepines, Benzos = GABA-A Benzo withdrawal can
Anxiolytics buspirone, Z-drugs, agonists; avoid in cause seizures; taper
& hydroxyzine elderly (BEERS); slowly, especially
Hypnotics buspirone = serotonin alprazolam
1A partial agonist, no
dependence
9. CBT, DBT, IPT, MI, CBT = cognitive DBT is first-line for
Psychother Exposure, Family distortions + BPD; CBT is first-line
apy behavioral activation; for MDD, GAD, panic,
DBT = 4 modules for PTSD
BPD; MI = OARS for
SUD
10. Capacity, Tarasoff, Capacity = Zuranolone = oral for
Legal/Ethic involuntary decision-specific; PPD; brexanolone = IV
s & Special commitment, Tarasoff = duty to for PPD; SSRIs = black
Population perinatal, geriatric, warn/protect box <25 years
s SUD identifiable victims;
minors = consent
varies by state
PART 2: PRACTICE QUESTIONS
